Reported Sunday, Viking Therapeutics Reports 74% Of Subcutaneous VK2735 Participants Improved BMI Category Versus 15% On Placebo After 13 Weeks, With Improved Cardiometabolic Markers

Benzinga · 3d ago

VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 Weeks

VK2735 Treatment Led to Improvement Across Multiple Cardiometabolic Markers